Table 2.

Ratios of doses studied or derived from onabotA:abobotA in clinical studies. Adapted from Ferrari et al., 2018 [114].

Indication	Author/Publication	RatioI (ona-botA:abobotA)
Blepharospasm	Bentivoglio et al., 2012 [115]	1:1.2–1:13.3
	Bihari, 2005 [116]	1:4–1:5
	Dodel et al., 1997 [117]	1:4–1:6
	Kollewe et al., 2015 [118]	1:2.3
	Marion et al., 1995 [119]	1:3
	Marchetti et al., 2005 [120]	1:3–1:11
	Nussgens and Roggenkämper, 1997 [121]	1:4
	Sampaio et al., 1997 [122]	1:4
Cervical dystonia	Bihari, 2005 [116]	1:4–1:5
	Dodel et al., 1997 [117]	1:4–1.6
	Marchetti et al., 2005 [120]	1:3–1:11
	Misra et al., 2012 [123]	3.1:1
	Odergren et al., 1998 [124]	1:3
	Ranoux D et al., 2002 [125]	1:3–1:4
	Rystedt A et al., 2015 [126]	1.7:1
	Van den Bergh and Lison, 1998 [127]	1:2.5
	Yun et al., 2015 [128]	1:2.5
Hemifacial spasm	Bihari, 2005 [116]	1:4–1:5
	Dodel et al., 1997 [117]	1:4–1:6
	Marion et al., 1995 [119]	1:3
	Van den Bergh and Lison, 1998 [127]	1:2.5
Spasticity	Bhakta et al., 1996 [129]	1:4–1:5
	Keren-Capelovitch et al., 2010 [130]	1:2.5
	Rasmussen et al., 2000 [131]	1:4